GLP-1 Obesity Drug Global Market Overview and 2026 Outlook
The GLP-1 (glucagon-like peptide-1) receptor agonist-based obesity therapeutics market is experiencing unprecedented growth. Goldman Sachs projects the global obesity drug market will reach $150 billion by 2035, while Morgan Stanley forecasts a compound annual growth rate (CAGR) exceeding 20%.
As of 2025, Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) command roughly 80% of the market in a duopoly structure. However, persistent supply shortages and high annual treatment costs (exceeding $12,000) present clear opportunities for challengers. Global pharma giants including Pfizer, Roche, and Amgen, as well as Korean companies such as Hanmi Pharmaceutical and Yuhan Corporation, are aggressively building next-generation GLP-1 pipelines.
Differentiated Market Entry Strategies for Korean SME Biotech
Targeting Unmet Needs Through Formulation Innovation
Most approved GLP-1 obesity treatments currently require once-weekly subcutaneous injections. Formulation differentiation—including oral formulations, microneedle patches, and long-acting monthly injectables—represents a core strategy for SMEs to enter the market without directly competing against big pharma. Given that oral semaglutide (Rybelsus) has a bioavailability below 1%, drug delivery systems (DDS) that dramatically improve absorption rates hold significant licensing value.
Next-Generation Multi-Mechanism Drug Development
Combination-mechanism drugs addressing the key limitation of GLP-1 monotherapy—muscle mass loss (25–40% of weight lost comes from lean mass)—are emerging as next-generation blockbuster candidates. Triple agonists targeting GLP-1/GIP/glucagon, activin receptor blockers for muscle preservation, and amylin analog combinations that simultaneously improve metabolic function and preserve muscle offer SMEs a meaningful area for research differentiation.
Entering the Supply Chain via CDMO Services
The global surge in GLP-1 demand has driven rapid growth in the peptide CDMO (contract development and manufacturing organization) market. Beyond major biosimilar manufacturers like Samsung Biologics and Celltrion, SMEs with specialized peptide synthesis and purification capabilities have expanding opportunities to participate as GLP-1 active pharmaceutical ingredient (API) supply partners. This path offers lower initial investment requirements compared to novel drug development and enables stable revenue generation.
Leveraging Government R&D Support Programs
Bio-Dedicated Funds and National Drug Development Programs
The Korean government has designated the bio-pharmaceutical industry as a national strategic technology sector and operates substantial support frameworks.
Government Support Roadmap from Clinical Trials to Approval
Risk Management and KITIM Consulting Support
Entering the GLP-1 obesity drug market involves substantial risks including patent barriers, regulatory uncertainty, and significant clinical trial costs.
KITIM (Korea Institute of Technology Innovation Management) provides comprehensive support for SME biotech companies, including government R&D proposal development, strategic planning for programs such as the National New Drug Development Program and TIPS, and stage-by-stage government support roadmap design for clinical development. If you need tailored consulting for GLP-1 obesity drug market entry, please reach out through our [Contact Page](/contact) to schedule a consultation.